



**HAL**  
open science

## Impact of patient ancestry on heterogeneity of Sjögren's disease

Maxime Beydon, Raphaele Seror, Véronique Le Guern, Pascale Chretien,  
Xavier Mariette, Gaetane Nocturne

► **To cite this version:**

Maxime Beydon, Raphaele Seror, Véronique Le Guern, Pascale Chretien, Xavier Mariette, et al..  
Impact of patient ancestry on heterogeneity of Sjögren's disease. RMD Open, 2023, 9 (1), pp.e002955.  
10.1136/rmdopen-2022-002955 . hal-04261148

**HAL Id: hal-04261148**

**<https://hal.science/hal-04261148>**

Submitted on 26 Oct 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Impact of patient ancestry on heterogeneity of Sjögren's disease

Maxime Beydon<sup>1,4</sup>, Raphaële Seror<sup>1,2</sup>, Véronique Le Guern<sup>3</sup>, Pascale Chrétien<sup>5</sup>, Xavier Mariette<sup>1,2</sup>, Gaëtane Nocturne<sup>1,2</sup>

<sup>1</sup>Department of Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Le Kremlin Bicêtre, France

<sup>2</sup>INSERM UMR1184 : Center for immunology of viral infections and autoimmune diseases, Université Paris Saclay, Le Kremlin-Bicêtre, France

<sup>3</sup> Department of Internal Medicine, Assistance Publique - Hôpitaux de Paris, Hôpital Cochin, Paris, France

<sup>4</sup> Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, F75013, Paris, France

<sup>5</sup> Université de Paris, CNRS, INSERM, UTCBS, Unité des technologies Chimiques et Biologiques pour la Santé, F-75006 Paris, France.

### **Abstract:**

**Objectives:** We aimed to compare disease characteristics between pSS patients of African ancestry (AA) and Caucasian ancestry.

**Methods:** We conducted a retrospective, case-control study in a French national and European referral center for pSS. All patients with pSS of AA were matched with two Caucasians patients having similar follow-up duration. We explored clinical and biological parameters associated with a cumESSDAI  $\geq 5$  (consisting of individual clinESSDAI domain maximum throughout follow-up).

**Results:** We identified 74 patients of AA matched with 148 Caucasian. Median age at pSS diagnosis was younger in AA patients (43 years [IQR 33-51] vs 56 years [44.8 – 59.2],  $p < 0.001$ ). AA patients presented higher median titer of gammaglobulins (18.5 g/L [IQR 15–22.8] vs 13.4 g/L [9.9–16.9],  $p < 0.001$ ,  $p < 0.001$ ), more frequently positive for anti-SSA (88% vs 72%,  $p = 0.007$ ) and anti-RNP (11% vs 2.7%,  $p = 0.023$ ) antibodies. During follow-up (median: 6 years [IQR 2-11]), AA patients presented more systemic complications: arthritis, myositis, interstitial lung disease, lymphadenopathy, central nervous system involvement. Median cumESSDAI score was higher in AA patients (7.5 [IQR 3.2 – 16.0] vs 4.0 [IQR 2.0 – 9.0],  $p = 0.002$ ). Interestingly, in multivariate analyses, factors associated with disease activity were Sub-Saharan African ancestry (OR 2.65 [1.06;6.94]), rheumatoid factor (OR 2.50 [1.28;4.96]) and anti-RNP positivity (OR 11.1 [1.88;212]).

**Conclusion:** Patients of AA display higher disease activity with a hallmark of higher B-cell activation. Studies to investigate biological drivers behind such differences are needed.

Abstract word count: 237,

Text word count:2131,

Tables: 3, Figures: 2 (total 5/6),

Supplemental:1 figure

Conflict of interest:

MB: none

RS: consulting fees from GSK, BMS, Boehringer, Jansen; payment or Honoraria from GSK, BMS, Fresenius Kabi, Boehringer, Jansen, Amgen, Pfizer, Roche; support for meeting attendance or travel from Amgen, GSK, Astra Zeneca

VLG: consulting fees from Novartis; payment or Honoraria from Bristol-Myers-Squibb; support for meeting attendance or travel Astra Zeneca

GN: consulting fees from Biogen, Pfizer, Novartis, Lilly and Amgen; participating in Advisory board for Boehringer Ingelheim; support for meeting attendance or travel Amgen

XM: consulting fees from Astra Zeneca, BMS, Galapagos, GSK, Novartis, Pfizer

PC: none

Corresponding author: Gaetane Nocturne, Service de Rhumatologie – Hôpital Kremlin Bicêtre, 78 Avenue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France. [gaetane.nocturne@aphp.fr](mailto:gaetane.nocturne@aphp.fr)

Data availability statement: All data can be made available upon reasonable request.

Funding: Assistance Publique des Hôpitaux de Paris (AP-HP)

Authors contribution:

MB, RS, GN, and XM conceived and designed the analysis;

MB, RS, GN, and VL collected the data;

RS, XM, GN and VLG contributed data;

MB performed the analysis;

MB, GN, VLG, XM, RS and GN contributed to data interpretation;

MB, XM, RS and GN wrote the paper;

PC provided support for reviewing

**Key messages:****What is already known about this subject?**

- In systemic lupus erythematosus (SLE), patients of African ancestry present higher disease activity, morbidity and higher mortality in case of end stage renal disease than other patients.
- Primary Sjögren's syndrome (pSS) shares, in some aspects, a common pathogenic framework with SLE, however, we found no longitudinal study that comprehensively compared symptoms, disease activity over time or treatments in patients of African ancestry to other ethnicity.

**What does this study add?**

- Our study is the first to reveal that African ancestry, particularly Sub-Saharan African ancestry, is an independent driver of a higher disease activity with distinct domain involved and autoantibody profile.

**How might this impact on clinical practice?**

- Physicians should be particularly aware of the over-representation of infrequent organ activity such as muscular, pulmonary and central nervous system involvement in patients of African ancestry.

## **Introduction**

Autoimmune diseases are complex by nature. In some people with specific genetic background, environmental triggers encountering genetic dysregulation might lead to over-stimulation of the immune system. This interaction between genetics and environment might promote loss of tolerance leading to the development of autoimmunity. In some diseases, it has been shown that ethnicity can influence disease phenotype. This is notably the case in systemic lupus erythematosus (SLE), in which disease burden is higher in patients from African ancestry (AA) than in Caucasian patients, with more end stage renal disease and higher mortality<sup>1</sup>. In addition, ethnicity might also influence the treatment response in lupus nephritis (LN)<sup>2</sup>. Socio-economics factors could in part explain these differences, as the interaction between ethnicity and poverty has been associated with disease activity<sup>3</sup>, along with genetic polymorphisms<sup>4-6</sup>.

Although primary Sjögren disease (pSS) and SLE vary by their clinical presentation, they share common pathogenic background including interferon (IFN) signature<sup>7</sup> and B cell activation. Increase in B-cell activating factor (BAFF) is at the crossroad between these diseases. Its overexpression is well described in both diseases and may favor development of auto-reactive lymphocytes<sup>8</sup>.

Data focusing on ethnicity and its impact in pSS is scarce. A study found pSS to be twice as frequent in non-European individuals than in Europeans<sup>9</sup>. In another report, ethnicity influenced prevalence of sicca symptoms along with biological parameters such as anti-nuclear (ANA) and anti-SSA/Ro antibodies positivity<sup>10</sup>. None of these studies focused specifically on patients of AA.

In this study, we described and compared demographic characteristics, biological parameters, disease activity, outcome and treatment in pSS patients of AA with matched Caucasian controls from two departments of a French national and European referral center for SS.

## **Methods**

### **Study design and setting**

We have conducted a retrospective case-control study. Eligible patients were screened in two departments belonging to a French national and European referral center for SS either through out patients' records for suspicion and follow-up of SS, or inpatients with an International Disease Classification (ICD)-10 code for SS.

### **Participants**

Cases were defined as pSS patients of AA. All cases fulfilled ACR/EULAR 2016 criteria for pSS and did not meet diagnostic criteria for other connective tissue diseases such as rheumatoid arthritis, SLE, scleroderma or mixed connective tissue disease. Patients who presented an associated connective

tissue disease at pSS diagnosis or during follow-up were excluded. Ancestry based on parents' origin was either self-declared if patients attended a standardized visit for suspicion of SS, or otherwise reported by physicians. Patients were not included if ancestry could not be ascertained. Each patient of AA has been paired with two randomly selected Caucasian controls from the same center. In order to properly compare disease activity over time, we also matched cases and controls based on follow-up duration, thus limiting selection bias.

### **Variables and data sources**

Based on computerized and paper medical files, we retrospectively collected sex, age at beginning of symptoms and age at diagnosis of pSS. We gathered Sjögren's related symptoms such as sicca, parotid gland enlargement and extra-glandular manifestations of pSS including occurrence of lymphoma at any time before or after diagnosis. Biological and immunological features included anti-nuclear antibodies (ANA), anti-SSA/Ro, anti-SSB/La, anti-DNA, anti-Sm and anti-RNP, gammaglobulins and  $\beta$ 2-microglobulinemia titers, complement levels and presence of cryoglobulinemia. We gathered histologic data of accessory salivary glands biopsies. We assessed EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) at each consult with available information and retained each category's maximum ESSDAI score during follow-up. We then calculated a cumulative ESSDAI (cumESSDAI) score per patient as the sum of each category's maximum score during follow-up. Using the same method, we calculated a cumulative ClinESSDAI (cumClinESSDAI) score, a variant which excludes the biological domain<sup>11</sup>. We additionally calculated a median EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score per patient when possible. Lastly, we gathered any pSS related treatments prescribed at diagnosis and onward.

### **Statistical analysis**

Our main analysis consisted of comparing patients of AA and Caucasians. We subsequently explored demographic, clinical and biological characteristics in patients of AA (sub-Saharan African and Afro-Caribbean) and of Caucasian ancestry. Lastly, we explored clinical and biological parameters associated with a cumulative clinESSDAI  $\geq 5$ . We used as outcome clinESSDAI rather than ESSDAI in order to explore gammaglobulin titers, cryoglobulin and low complement level.

Data are presented as mean  $\pm$  (SD) or medians [Interquartile range (IQR)] as appropriate for continuous variables and number (%) for qualitative variables. Wilcoxon rank test and one-way analysis of variance tests were used to compare continuous variables. Chi-square or Fisher's exact test was used to compare categorical features. In order to investigate clinical and biological parameters associated with an elevated clinESSDAI, After exploring variables associated with a cumClinESSDAI  $\geq 5$  in an univariate binomial logistic regression, we integrated in a multivariate logistic regression model all variables with  $p < 0,15$ . Statistical analysis were performed on R version 4.2.1.

### **Consent and ethical statement**

All study subjects provided their informed consent for data collection including ancestry (IRB Paris Sud #00-17).

### **Patients and Public involvement**

No patients or public were involved in the design, reporting or dissemination of our study.

## **Results**

### **Differences between pSS patients of African and Caucasian ancestry**

Of the 1269 pSS patients fulfilling ACR/EULAR 2016 diagnostic criteria, we identified 74 patients of AA to whom we matched 148 Caucasian patients based on follow-up duration and center. A detailed flow chart is presented in Figure S1. Median follow-up duration was of 6.0 years [IQR 2.0–11.0] in both groups. Median age at pSS diagnosis was younger in AA patients than in Caucasians (43 years [IQR 33.0–51.0] vs 56.0 years [44.8–59.2],  $p < 0.001$ ), with similar proportion of female across groups (92% vs 94% respectively,  $p = 0.6$ ). Median delay between first symptoms and diagnosis was not statistically difference between patients of AA and Caucasians (2.0 years [IQR 0.0-4.0] vs 2.0 years [IQR 1-7] respectively,  $p = 0.06$ ) (Figure S2). During follow-up, patients of AA presented more frequently with arthritis (27% vs 12%,  $p = 0.006$ ), myositis (5.4% vs 0.7%,  $p = 0.043$ ), interstitial lung disease (ILD) (11% vs 3.4%,  $p = 0.035$ ), lymphadenopathy (26% vs 10%,  $p = 0.002$ ), pSS related central nervous system affliction (5.4% vs 0.7%,  $p = 0.43$ ). Caucasians tended to present more frequently with axonal neuropathy (1.4% vs 8.1%,  $p = 0.065$ ). Results are presented in Table 1.

Regarding immunologic work-up, AA patients presented higher median titers of gammaglobulins (18.5 g/L [IQR 15–22.8] vs 13.4 g/L [9.9–16.9],  $p < 0.001$ ) and were more frequently positive for anti-SSA (88% vs 72%,  $p = 0.007$ ) and anti-RNP (11% vs 2.7%,  $p = 0.023$ ). Of note, we initially detected 4 AA patients with anti Sm/nRNP but after careful checking using immunodot, three of these 4 patients had anti Sm/nRNP that are less specific of SLE<sup>12</sup> and only one had isolated anti Sm. None of these 4 patients had specific features of SLE. Caucasians tended to present more frequently with positive rheumatoid factor (41% vs 53%,  $p 0.07$ ). One and four patients in the AA and Caucasian group respectively presented with measurable anti-DNA antibodies positivity on one or more occasion during follow-up (median follow up of 15 years [IQR 9–15]). None of these patients presented SLE clinical manifestations such as acute cutaneous lupus or LN.

Overall disease activity, assessed by cumESSDAI, was higher in AA patients with a median cumESSDAI score of 7.5 [IQR 3.2–16.0] vs 4.0 [IQR 2.0–9.0] in Caucasians ( $p = 0.002$ ) (Figure 1A). This difference remained when comparing cumClinESSDAI (Table 1). Patients of AA presented more frequently with activity in the constitutional, pulmonary, lymphadenopathy, muscular, central nervous

system and biological domains (Figure 1B). Frequency of prescription of steroids, hydroxychloroquine and immunosuppressors was not different between both groups (Table1).

### **Does origin of African Ancestry influence pSS manifestations?**

Among the AA population, we distinguished 43 patients of sub-Saharan African ancestry and 31 of Afro-Caribbean ancestry. As shown in table 2, most statistical differences between AA patients and Caucasians are limited to the sub-Saharan African ancestry population, except for age at pSS diagnosis, ocular dryness and serum gammaglobulins level which followed similar trends in Afro-Caribbean and sub-Saharan African patients. Of note, median cumESSDAI score was not different between Afro-Caribbean and Caucasians (6.0 [IQR 2.0–12.0] vs 4.5 [IQR 2.0–9.0] respectively,  $p = 0.5$ ) contrarily to sub-Saharan African ancestry patients (9.0 [IQR 4.0–17.0] vs 4.5 [IQR 2.0–9.0],  $p < 0.001$ ) (Figure 2). In the sub-Saharan African group, immunosuppressors were more frequently prescribed than in the Caucasian group (37% vs 21%,  $p = 0.029$ ).

### **African Ancestry as an independent driver of disease activity**

We observed that AA patients had more biomarkers of B cells activation and a higher cumulative disease activity. These two parameters have been shown to be associated in pSS<sup>13</sup>. We therefore investigated whether ancestry remained associated with disease activity independently of biological markers. In table 3, we present results of univariate and multivariate analysis of features associated with a clinCumESSDAI  $\geq 5$ . In the univariate analysis, we found that disease activity was associated with sub-Saharan African ancestry (OR 2.58 [1.26, 5.59]), with higher follow-up duration (OR 2.58 [1.26;5.59]), rheumatoid factor (OR 2.45 [1.43;4.25]), anti-RNP (OR 9.81 [1.86;181]) and cryoglobulin positivity (OR 2.64 [1.28;5.80]). We also found an inverse correlation with age at pSS diagnosis (OR 0.978 [0.960;0.996]). In multivariate analysis, Sub-Saharan African ancestry was independently associated with higher disease activity (OR 2.65 [1.06;6.94]), as well as rheumatoid factor (OR 2.50 [1.28;4.96]) and anti-RNP positivity (OR 11.1 [1.88;212]).

## **Discussion**

This study is the first to compare demographic, clinical and biological characteristics of pSS patients of AA with Caucasians. We observed that patients of AA were younger at diagnosis, presented higher rates of arthritis, myositis, ILD, lymphadenopathy and CNS involvement. They had higher anti-RNP positivity and higher titers of gammaglobulins. Disease activity was higher in patients of AA compared with Caucasians as reflected by the cumESSDAI score.

Brito-Zeron et al. showed, consistent with our results, that African-American pSS patients had younger disease onset compared to white pSS patients with higher titers of anti-SSA antibodies<sup>10</sup>.



Anti-SSA positivity in pSS has been showed to be associated with younger age at diagnosis, higher prevalence of lymphoma, of purpura and of salivary gland enlargement<sup>14</sup>. Regarding biological characteristics, anti-SSA positivity has been shown to be associated with higher rates of hypergammaglobulins, with rheumatoid factor positivity and low complement levels<sup>14</sup>. Although patients of AA were younger than Caucasians with higher rates of hypergammaglobulinemia, the phenotypic differences we observed between the two populations does not appear to be solely related to anti-SSA positivity since lymphomas, purpura and glandular domains were equally frequent.

Interestingly, higher disease activity in AA patients was restricted to patients from sub-Saharan African ancestry and not found in patients of Afro-Caribbean ancestry. Although some common genetic background is shared between Afro-Caribbean and continental African populations<sup>15</sup>, these two groups differ with notably Amerindian admixture in the populations of Afro-Caribbean origin<sup>16</sup>. In addition, it has been showed in SLE that environmental factors could play a role in populations with close ancestry<sup>17</sup>. Studying such differences might uncover candidate genes for drivers of autoimmunity in patients of AA.

Although B-cell activation markers were more prevalent in AA patients, and particularly in sub-Saharan African patients, we showed that these patients still displayed higher disease activity after adjusting for these biomarkers. We solely accounted for routine biological workup and could not evaluate more specific cytokines such as sBAFF, whose expression can vary depending on geographic origin<sup>18</sup>. The level of BAFF expression may be associated with genetic polymorphism; recently, a BAFF variant associated with increased serum BAFF level has been shown to participate in the increased risk of SLE and multiple sclerosis in a Sardinian population; this variant was probably selected through evolution by augmenting resistance to malaria<sup>18</sup>, mechanism that could be also very pregnant in an AA population. Moreover, we showed that anti-RNP positivity remained an independent predictor of disease activity and a possible distinct clinical phenotype of pSS patients with anti-RNP antibody as suggested in a previous study<sup>19</sup>.

One of our study's strengths is the effort made to depict patients' overall disease phenotype overtime rather than presenting a snapshot of disease activity in cross-sectional designs. Indeed, pSS evolves by flares intertwined with remission periods that can sometime last years. Therefore, when comparing disease burden with treatment prescription over time and long-term complications such as lymphoma occurrence, longitudinal studies are most adapted. Moreover, in order to limit selection bias, we ensured cases and controls had similar opportunity of presenting disease-related complications by matching on follow-up duration.

A limit to our study is its setting in tertiary center without primary care data. One could argue that differences between groups could be explained by socio-economic factors with unequal access to healthcare facilities in one group, which might underestimate prevalence of less severe cases whilst

over-representing severe patients. However, France's healthcare access is free and universal without conditioning on employment, wealth nor immigration status, limiting such bias. Moreover, patients of AA are diagnosed at a younger age than Caucasian patients, are younger at symptoms onset and do not seem to suffer from diagnostic delay which might be at the origin of higher disease activity. We even observed a tendency towards greater delay in Caucasian patients, possibly because of lesser disease activity. We could not however adjust for income and education and therefore could not evaluate their impact on disease activity. Another limit of our study is its retrospective nature, which we justified by focusing mostly on standard information regarding pSS follow-up such as biological data, domain activity at each visit and treatments.

In conclusion, pSS patients of AA, notably of Sub-Saharan African ancestry, had a distinct disease expression compared to Caucasians pSS patients. More studies are needed to determine the drivers behind these phenotypic differences.

1. Sule S, Fivush B, Neu A, Furth S. Increased risk of death in African American patients with end-stage renal disease secondary to lupus. *Clin Kidney J.* 2014;7(1):40-44. doi:10.1093/ckj/sft157
2. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis. *JASN.* 2009;20(5):1103-1112. doi:10.1681/ASN.2008101028
3. Alarcón GS, McGwin G, Sanchez ML, et al. Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity. *Arthritis Care & Research.* 2004;51(1):73-77. doi:https://doi.org/10.1002/art.20085
4. Ramos PS, Oates JC, Kamen DL, et al. Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry. *J Rheumatol.* 2013;40(6):842-849. doi:10.3899/jrheum.120989
5. Sibanda EN, Chase-Topping M, Pfavayi LT, Woolhouse MEJ, Mutapi F. Evidence of a distinct group of Black African patients with systemic lupus erythematosus. *BMJ Glob Health.* 2018;3(5):e000697. doi:10.1136/bmjgh-2017-000697
6. Sánchez E, Comeau ME, Freedman BI, et al. Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. *Arthritis & Rheumatism.* 2011;63(11):3493-3501. doi:https://doi.org/10.1002/art.30563
7. Nguyen CQ, Peck AB. The Interferon-Signature of Sjögren's Syndrome: How Unique Biomarkers Can Identify Underlying Inflammatory and Immunopathological Mechanisms of Specific Diseases. *Front Immunol.* 2013;4:142. doi:10.3389/fimmu.2013.00142
8. Bird AK, Meednu N, Anolik JH. New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome. *Current Opinion in Rheumatology.* 2015;27(5):461-467. doi:10.1097/BOR.0000000000000201
9. Maldini C, Seror R, Fain O, et al. Epidemiology of Primary Sjögren's Syndrome in a French Multiracial/Multiethnic Area. *Arthritis Care & Research.* 2014;66(3):454-463. doi:10.1002/acr.22115
10. Brito-Zerón P, Acar-Denizli N, Zeher M, et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. *Ann Rheum Dis.* 2017;76(6):1042-1050. doi:10.1136/annrheumdis-2016-209952
11. Seror R, Meiners P, Baron G, et al. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. *Ann Rheum Dis.* 2016;75(11):1945-1950. doi:10.1136/annrheumdis-2015-208504
12. Sharp GC, Irvin WS, LaRoque RL, et al. Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. *J Clin Invest.* 1971;50(2):350-359. doi:10.1172/JCI106502
13. Mingueneau M, Boudaoud S, Haskett S, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. *J Allergy Clin Immunol.* 2016;137(6):1809-1821.e12. doi:10.1016/j.jaci.2016.01.024

14. Quartuccio L, Baldini C, Bartoloni E, et al. Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. *Autoimmunity Reviews*. 2015;14(11):1019-1022. doi:10.1016/j.autrev.2015.07.002
15. Murray T, Beaty TH, Mathias RA, et al. African and Non-African Admixture Components in African Americans and An African Caribbean Population. *Genet Epidemiol*. 2010;34(6):10.1002/gepi.20512. doi:10.1002/gepi.20512
16. Moreno-Estrada A, Gravel S, Zakharia F, et al. Reconstructing the Population Genetic History of the Caribbean. *PLOS Genetics*. 2013;9(11):e1003925. doi:10.1371/journal.pgen.1003925
17. Molokhia M, Mckeigue P. Systemic lupus erythematosus: genes versus environment in high risk populations. *Lupus*. 2006;15(11):827-832. doi:10.1177/0961203306070007
18. Steri M, Orrù V, Idda ML, et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk. *N Engl J Med*. 2017;376(17):1615-1626. doi:10.1056/NEJMoa1610528
19. Abbara S, Seror R, Henry J, et al. Anti-RNP positivity in primary Sjögren's syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement. *RMD Open*. 2019;5(2):e001033. doi:10.1136/rmdopen-2019-001033

## TABLES

Table 1: Demographic, clinical and biological characteristics of pSS patients according to ancestry

	African, N = 74 <sup>1</sup>	Caucasian, N = 148 <sup>1</sup>	p-value <sup>2</sup>
Follow-up duration	6.0 (2.0, 11.0)	6.0 (2.0, 11.0)	>0.9
Age at symptoms onset	40.0 (30.0, 48.0)	52.0 (37.8, 59.2)	<b>&lt;0.001</b>
Age at Sjögren's diagnosis	43.0 (33.0, 51.0)	56.0 (44.8, 64.0)	<b>&lt;0.001</b>
Sex, Female	68 / 74 (92%)	139 / 148 (94%)	0.6
Fatigue	43 / 52 (83%)	72 / 138 (52%)	<b>&lt;0.001</b>
Oral dryness	61 / 74 (82%)	133 / 148 (90%)	0.12
Eye dryness	53 / 74 (72%)	127 / 148 (86%)	<b>0.011</b>
Schirmer abnormal	29 / 46 (63%)	74 / 108 (69%)	0.5
Low salivary flux	12 / 41 (29%)	37 / 95 (39%)	0.3
Chisholm score 3-4	55 / 66 (83%)	96 / 123 (78%)	0.4
Raynaud syndrome	20 / 74 (27%)	34 / 148 (23%)	0.5
Salivary gland enlargement	31 / 74 (42%)	50 / 148 (34%)	0.2
Arthritis	20 / 74 (27%)	18 / 148 (12%)	<b>0.006</b>
Myositis	4 / 74 (5.4%)	1 / 148 (0.7%)	<b>0.043</b>
Pulmonary involvement	13 / 74 (18%)	16 / 148 (11%)	0.2
ILD	8 / 74 (11%)	5 / 148 (3.4%)	<b>0.035</b>
Lymphadenopathy	19 / 74 (26%)	15 / 148 (10%)	<b>0.002</b>
Splenomegaly	0 / 74 (0%)	2 / 148 (1.4%)	0.6
Subacute cutaneous lupus	0 / 74 (0%)	6 / 148 (4.1%)	0.2
Purpura	6 / 74 (8.1%)	15 / 148 (10%)	0.6
CNS involvement	4 / 74 (5.4%)	1 / 148 (0.7%)	<b>0.043</b>
Retrobulbar optic neuritis	1 / 4 (25%)	0 / 1 (0%)	-
Cerebral vasculitis	2 / 4 (0%)	0 / 1 (0%)	-
Acute demyelinating encephalomyelitis	1 / 4 (25%)	0 / 1 (0%)	-
Transverse myelitis	0 / 4 (0%)	1 / 1 (0%)	-
PNS involvement	2 / 74 (2.7%)	13 / 148 (8.8%)	0.15
Renal involvement	4 / 74 (5.4%)	6 / 148 (4.1%)	0.7
Lymphoma	6 / 74 (8.1%)	6 / 148 (4.1%)	0.2
Gammaglobulins titer (g/l)	18.5 (15.0, 22.8)	13.4 (9.9, 16.9)	<b>&lt;0.001</b>
β2-microglobulin titer (mg/L)	2.3 (1.9, 2.7)	2.2 (1.8, 2.9)	>0.9
Rheumatoid Factor	30 / 74 (41%)	79 / 148 (53%)	0.071
anti-SSA	65 / 74 (88%)	106 / 148 (72%)	<b>0.007</b>
anti-SSB	28 / 74 (38%)	58 / 148 (39%)	0.8
anti-DNA	1 / 74 (1.4%)	4 / 148 (2.7%)	0.7
anti-Sm	1 / 74 (1.4%)	0 / 148 (0%)	0.3
anti-RNP	8 / 74 (11%)	4 / 148 (2.7%)	<b>0.023</b>
Cryoglobulinemia	15 / 74 (20%)	26 / 148 (18%)	0.6
Low C3	0 / 74 (0%)	6 / 148 (4.1%)	0.2
Low C4	14 / 74 (19%)	35 / 148 (24%)	0.4
ESSPRI	6.0 (4.5, 7.3)	5.7 (4.4, 6.6)	0.8
cumESSDAI	7.5 (3.2, 16.0)	4.0 (2.0, 9.0)	<b>0.002</b>
cumClinESSDAI	8.0 (2.0, 15.0)	4.5 (2.0, 9.0)	<b>0.011</b>
Steroids	23 / 74 (31%)	48 / 148 (32%)	0.8
Immunosuppressors	20 / 74 (27%)	31 / 148 (21%)	0.3

Table 1: Demographic, clinical and biological characteristics of pSS patients according to ancestry

	African, N = 74 <sup>1</sup>	Caucasian, N = 148 <sup>1</sup>	p-value <sup>2</sup>
Number immunosuppressors			0.5
0	54 / 74 (73%)	117 / 148 (79%)	
1	14 / 74 (19%)	23 / 148 (16%)	
≥ 2	6 / 74 (8.1%)	8 / 148 (5.4%)	

<sup>1</sup>Median (IQR); n / N (%) <sup>2</sup>Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test  
 ILD: interstitial lung disease, CNS: central nervous system.

Table 2: Demographic, clinical and biological characteristics of pSS patients according to ancestry in sub-group populations

	Caucasian vs Sub Saharan			Caucasian vs Afro Caribbean	
	Caucasian, N = 148 <sup>1</sup>	Sub Saharan, N = 43 <sup>1</sup>	p-value <sup>2</sup>	Afro Caribbean, N = 31 <sup>1</sup>	p-value <sup>2</sup>
Follow-up duration	6.0 (2.0, 11.0)	5.0 (2.5, 11.0)	>0.9	6.0 (2.0, 11.5)	0.9
Age at symptoms onset	52.0 (37.8, 59.2)	35.5 (25.5, 44.0)	<b>&lt;0.001</b>	44.5 (36.5, 51.0)	<b>0.047</b>
Age at Sjögren's diagnosis	56.0 (44.8, 64.0)	40.0 (31.0, 48.0)	<b>&lt;0.001</b>	47.0 (36.5, 53.5)	<b>&lt;0.001</b>
Sex, Female	139 / 148 (94%)	39 / 43 (91%)	0.5	29 / 31 (94%)	>0.9
Fatigue	72 / 138 (52%)	26 / 31 (84%)	<b>0.001</b>	17 / 21 (81%)	<b>0.013</b>
Oral dryness	133 / 148 (90%)	33 / 43 (77%)	<b>0.025</b>	28 / 31 (90%)	>0.9
Eye dryness	127 / 148 (86%)	31 / 43 (72%)	<b>0.036</b>	22 / 31 (71%)	<b>0.044</b>
Shiermer abnormal	74 / 108 (69%)	16 / 28 (57%)	0.3	13 / 18 (72%)	0.8
Low salivary flux	37 / 95 (39%)	7 / 27 (26%)	0.2	5 / 14 (36%)	0.8
Chisholm score 3-4	96 / 123 (78%)	34 / 40 (85%)		21 / 26 (81%)	0.8
Lymphoma	6 / 148 (4.1%)	3 / 43 (7.0%)	0.4	3 / 31 (9.7%)	0.2
Gammaglobulins titer (g/L)	13.4 (9.9, 16.9)	19.6 (14.7, 24.2)	<b>&lt;0.001</b>	17.6 (15.0, 21.0)	<b>&lt;0.001</b>
β2-microglobulintiter (mg/L)	2.2 (1.8, 2.9)	2.3 (2.0, 2.7)	>0.9	2.2 (1.9, 2.7)	0.8
Rheumatoid Factor	79 / 148 (53%)	17 / 43 (40%)	0.11	13 / 31 (42%)	0.2
anti-SSA	106 / 148 (72%)	38 / 43 (88%)	<b>0.025</b>	27 / 31 (87%)	0.073
anti-SSB	58 / 148 (39%)	20 / 43 (47%)	0.4	8 / 31 (26%)	0.2
anti-DNA	4 / 148 (2.7%)	0 / 43 (0%)	0.6	1 / 31 (3.2%)	>0.9
anti-SM	0 / 148 (0%)	1 / 43 (2.3%)	0.2	0 / 31 (0%)	
anti-RNP	4 / 148 (2.7%)	7 / 43 (16%)	<b>0.003</b>	1 / 31 (3.2%)	>0.9
Cryoglobulinemia	26 / 148 (18%)	8 / 43 (19%)	0.9	7 / 31 (23%)	0.5
Low C3	6 / 148 (4.1%)	0 / 43 (0%)	0.3	0 / 31 (0%)	0.6
Low C4	35 / 148 (24%)	9 / 43 (21%)	0.7	5 / 31 (16%)	0.4
cumClinESSDAI	4.5 (2.0, 9.0)	9.0 (4.0, 18.0)	<b>0.002</b>	6.0 (2.0, 12.0)	0.5
Steroid prescription	48 / 148 (32%)	19 / 43 (44%)	0.2	4 / 31 (13%)	<b>0.029</b>
Immunosuppressors	31 / 148 (21%)	16 / 43 (37%)	<b>0.029</b>	4 / 31 (13%)	0.3

<sup>1</sup>n / N (%); Median (IQR) <sup>2</sup>Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test

\*Patients with any level of activity during follow-up

CNS: central nervous system, PNS: peripheral nervous system,





Table 3: Univariate and multivariate analysis of parameters associated with a clinCumESSDAI  $\geq 5$ 

Characteristic	Univariate analysis			Multivariate analysis <sup>2</sup>		
	OR <sup>1</sup>	95% CI <sup>1</sup>	p-value	OR <sup>1</sup>	95% CI <sup>1</sup>	p-value
Origin						
Caucasian	—	—		—	—	
Afro Caribbean	1.21	0.56, 2.68	0.62	1.53	0.61, 3.94	0.4
Sub Saharan	2.58	1.26, 5.59	<b>0.012</b>	2.65	1.06, 6.94	<b>0.040</b>
Follow-up duration	1.06	1.02, 1.11	<b>0.009</b>	1.04	0.99, 1.10	0.11
Age at Sjögren's diagnosis	0.978	0.960, 0.996	<b>0.021</b>	0.98	0.96, 1.01	0.2
Sex						
F	—	—		—	—	
M	0.70	0.24, 2.02	0.51	—	—	
Oral dryness	1.75	0.79, 3.96	0.17	—	—	
Eye dryness	1.14	0.58, 2.23	0.71	—	—	
Shiermer abnormal	0.98	0.50, 1.92	0.95	—	—	
Low salivary flux	1.01	0.50, 2.04	0.98	—	—	
Chisholm score						
0-2	—	—		—	—	
3-4	1.04	0.50, 2.13	0.91	—	—	
Gammaglobulins titer (g/L)	1.04	0.99, 1.08	0.11	0.98	0.92, 1.04	0.4
Rheumatoid Factor	2.45	1.43, 4.25	<b>0.001</b>	2.50	1.28, 4.96	<b>0.008</b>
anti-SSA	1.51	0.81, 2.84	0.20	—	—	
anti-SSB	1.44	0.84, 2.51	0.19	—	—	
anti-RNP	9.81	1.86, 181	<b>0.030</b>	11.1	1.88, 212	<b>0.028</b>
Cryoglobulin	2.64	1.28, 5.80	<b>0.011</b>	1.82	0.81, 4.28	0.2
Low C4	1.55	0.81, 3.03	0.19	—	—	

<sup>1</sup>OR = Odds Ratio, CI = Confidence Interval<sup>2</sup>multivariate analysis adjusted on ancestry, follow-up duration, age at sjögren's diagnosis, gammaglobulins titer, rheumatoid factor, cryoglobulin and anti-RNP positivity

## FIGURES

### **Figure 1: Cumulative ESSDAI score comparison and domain activity according to ancestry**

*Cumulative ESSDAI score according to ancestry (panel A), percentage of patients presenting any ESSDAI domain level of activity, low, moderate or high, during follow-up (panel B).*

*Bio: biological, pulm: pulmonary, musc: muscular, cns: central nervous system, pns: peripheral nervous system, ren: renal, hem: hematological, cut: cutaneous, art: articular, gla: glandular, lymph: lymphadenopathy, con: constitutional, \*:  $p < 0.05$  with fisher's exact test*

### **Figure 2: Cumulative ESSDAI score according to ancestry in subgroup populations**

*Cumulative ESSDAI score according to subgroups of ancestry \*\*\*:  $p < 0.001$  with fisher's exact test*